NTC announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its development product NTC015 (Kleerkol^®) for bowel preparation for colonoscopy

NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, with distribution partners in over 100 countries, announced today that it has entered into an exclusive agreement with Théa for NTC026

NTC Srl and I-MED Pharma Inc announced today that I-DEFENSE^®, a long-lasting, lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the U.S.A. Food and Drug Administration. It is the first European NTC medical device product for ophthalmic use approved in the U.S.A.